{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:41:12Z","timestamp":1777480872623,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,31]]},"DOI":"10.7759\/cureus.68316","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T17:54:45Z","timestamp":1725126885000},"source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of Coenzyme Q10 Supplementation in Statin-Induced Myopathy: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Khoula","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naelijwa J","family":"Manongi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramkumar","family":"Rajapandian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajida","family":"Moti Wala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esraa M","family":"Al Edani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essa A","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana P","family":"Arcia Franchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and Stroke Statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao CW","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al.. Heart disease and Stroke Statistics-2022 update: a report from the American Heart Association. Circulation. 2022, 145:153-639. 10.1161\/CIR.0000000000001052","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-12-199406150-00008","article-title":"Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease","volume":"120","author":"Rader DJ","year":"1994","unstructured":"Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994, 120:1012-25. 10.7326\/0003-4819-120-12-199406150-00008","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117794","article-title":"The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans","volume":"95","author":"Rader DJ","year":"1995","unstructured":"Rader DJ, Mann WA, Cain W, et al.. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 1995, 95:1403-8. 10.1172\/JCI117794","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:122516","article-title":"Mortality in the United States, 2021","author":"Xu J","year":"2022","unstructured":"Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2021. NCHS data brief, no 456. National Center for Health Statistics, Hyattsville, MD; 2022. 1-8. 10.15620\/cdc:122516"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins R","year":"2016","unstructured":"Collins R, Reith C, Emberson J, et al.. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016, 388:2532-61. 10.1016\/S0140-6736(16)31357-5","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx468","article-title":"Low-density lipoprotein: the culprit. From evidence to counselling, drugs, and vaccination","volume":"38","author":"L\u00fcscher TF","year":"2017","unstructured":"L\u00fcscher TF. Low-density lipoprotein: the culprit. From evidence to counselling, drugs, and vaccination. Eur Heart J. 2017, 38:2447-50. 10.1093\/eurheartj\/ehx468","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman MG","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, et al.. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016, 316:1289-97. 10.1001\/jama.2016.13985","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio E","year":"2009","unstructured":"Di Angelantonio E, Sarwar N, Perry P, et al.. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009, 302:1993-2000. 10.1001\/jama.2009.1619","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon DJ","year":"1989","unstructured":"Gordon DJ, Probstfield JL, Garrison RJ, et al.. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989, 79:8-15. 10.1161\/01.cir.79.1.8","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.67.5.968","article-title":"Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study","volume":"67","author":"Hubert HB","year":"1983","unstructured":"Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983, 67:968-77. 10.1161\/01.cir.67.5.968","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.12.021","article-title":"Low HDL-C: a secondary target of dyslipidemia therapy","volume":"118","author":"Rosenson RS","year":"2005","unstructured":"Rosenson RS. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med. 2005, 118:1067-77. 10.1016\/j.amjmed.2004.12.021","journal-title":"Am J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049662","article-title":"Global prevalence of dyslipidaemia in adult populations: a systematic review protocol","volume":"11","author":"Mohamed-Yassin MS","year":"2021","unstructured":"Mohamed-Yassin MS, Baharudin N, Abdul-Razak S, Ramli AS, Lai NM. Global prevalence of dyslipidaemia in adult populations: a systematic review protocol. BMJ Open. 2021, 11:049662. 10.1136\/bmjopen-2021-049662","journal-title":"BMJ Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90\u2008056 participants in 14 randomised trials of statins","volume":"366","year":"2005","unstructured":"Efficacy and safety of cholesterol-lowering treatment. prospective meta-analysis of data from 90\u2008056 participants in 14 randomised trials of statins. Lancet. 2005, 366:1267-78. 10.1016\/S0140-6736(05)67394-1","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent C","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al.. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010, 376:1670-81. 10.1016\/S0140-6736(10)61350-5","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103304","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"74","author":"Abed W","year":"2022","unstructured":"Abed W, Abujbara M, Batieha A, Ajlouni K. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. Ann Med Surg (Lond). 2022, 74:103304. 10.1016\/j.amsu.2022.103304","journal-title":"Ann Med Surg (Lond)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.81.5.1721","article-title":"The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association","volume":"81","author":"LaRosa JC","year":"1990","unstructured":"LaRosa JC, Hunninghake D, Bush D, et al.. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation. 1990, 81:1721-33. 10.1161\/01.cir.81.5.1721","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.03.010","article-title":"Mechanisms of statin-associated skeletal muscle-associated symptoms","volume":"154","author":"Bouitbir J","year":"2020","unstructured":"Bouitbir J, Sanvee GM, Panajatovic MV, Singh F, Kr\u00e4henb\u00fchl S. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol Res. 2020, 154:104201. 10.1016\/j.phrs.2019.03.010","journal-title":"Pharmacol Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang H","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013, 158:526-34. 10.7326\/0003-4819-158-7-201304020-00004","journal-title":"Ann Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009, 6:1000100. 10.1371\/journal.pmed.1000100","journal-title":"PLoS Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009835","article-title":"Effects of Coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials","volume":"7","author":"Qu H","year":"2018","unstructured":"Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of Coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018, 7:009835. 10.1161\/JAHA.118.009835","journal-title":"J Am Heart Assoc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S223153","article-title":"Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study","volume":"13","author":"Derosa G","year":"2019","unstructured":"Derosa G, D'Angelo A, Maffioli P. Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. Drug Des Devel Ther. 2019, 13:3647-55. 10.2147\/DDDT.S223153","journal-title":"Drug Des Devel Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.890777","article-title":"Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study","volume":"20","author":"Skarlovnik A","year":"2014","unstructured":"Skarlovnik A, Jani\u0107 M, Lunder M, Turk M, \u0160abovi\u010d M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit. 2014, 20:2183-8. 10.12659\/MSM.890777","journal-title":"Med Sci Monit"},{"key":"ref25","article-title":"Assessment of some clinical and biochemical parameters after combining coenzyme Q10 to statin in dyslipidemic patients","volume":"11","author":"Yasser AN","year":"2021","unstructured":"Yasser AN, Abdulridha MK, Shafeek MA. Assessment of some clinical and biochemical parameters after combining coenzyme Q10 to statin in dyslipidemic patients. Int J Drug Deliv. 2021, 11:905-11.","journal-title":"Int J Drug Deliv"},{"key":"ref26","article-title":"The effect of coenzyme Q10 in statin myopathy","volume":"33","author":"Zlatohlavek L","year":"2012","unstructured":"Zlatohlavek L,Vrablik M, Grauova B, et al.. The effect of coenzyme Q10 in statin myopathy. Neuro Endocrinol Lett. 2012, 33:98-101.","journal-title":"Neuro Endocrinol Lett"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff L","year":"2007","unstructured":"Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007, 49:2231-7. 10.1016\/j.jacc.2007.02.049","journal-title":"J Am Coll Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach F","year":"2018","unstructured":"Mach F, Ray KK, Wiklund O, et al.. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018, 39:2526-39. 10.1093\/eurheartj\/ehy182","journal-title":"Eur Heart J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman CB","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, et al.. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019, 39:38-81. 10.1161\/ATV.0000000000000073","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica M","year":"2023","unstructured":"Ruscica M, Ferri N, Banach M, Sirtori CR, Corsini A. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2023, 118:3288-304. 10.1093\/cvr\/cvac020","journal-title":"Cardiovasc Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson RS","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014, 8:58-71. 10.1016\/j.jacl.2014.03.004","journal-title":"J Clin Lipidol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-017-6723-4","article-title":"The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability","volume":"31","author":"Rosenson RS","year":"2017","unstructured":"Rosenson RS, Miller K, Bayliss M, et al.. The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017, 31:179-86. 10.1007\/s10557-017-6723-4","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.07.008","article-title":"Statin therapy and plasma coenzyme Q10 concentrations--a systematic review and meta-analysis of placebo-controlled trials","volume":"99","author":"Banach M","year":"2015","unstructured":"Banach M, Serban C, Ursoniu S, et al.. Statin therapy and plasma coenzyme Q10 concentrations--a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015, 99:329-36. 10.1016\/j.phrs.2015.07.008","journal-title":"Pharmacol Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106046","article-title":"Association of statin induced reduction in serum coenzyme Q10 level and conduction deficits in motor and sensory nerves: an observational cross-sectional study","volume":"196","author":"Gurha N","year":"2020","unstructured":"Gurha N, Rehan HS, Yadav M, Gupta LK. Association of statin induced reduction in serum coenzyme Q10 level and conduction deficits in motor and sensory nerves: an observational cross-sectional study. Clin Neurol Neurosurg. 2020, 196:106046. 10.1016\/j.clineuro.2020.106046","journal-title":"Clin Neurol Neurosurg"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2023.07.003","article-title":"Mitochondrial dysfunction and skeletal muscle atrophy: Causes, mechanisms, and treatment strategies","volume":"72","author":"Kubat GB","year":"2023","unstructured":"Kubat GB, Bouhamida E, Ulger O, et al.. Mitochondrial dysfunction and skeletal muscle atrophy: Causes, mechanisms, and treatment strategies. Mitochondrion. 2023, 72:33-58. 10.1016\/j.mito.2023.07.003","journal-title":"Mitochondrion"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253828-effectiveness-of-coenzyme-q10-supplementation-in-statin-induced-myopathy-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T17:54:49Z","timestamp":1725126889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253828-effectiveness-of-coenzyme-q10-supplementation-in-statin-induced-myopathy-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.68316","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,31]]}}}